ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COGT vs MIRM // EV/EBITDA & P/E VALUATION

Cogent Biosciences Inc. (NASDAQ) VS. Mirum Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: COGT 3 — MIRM 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. MIRM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COGT MIRM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -3.90% -31.10 MIRM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -4.80% 0.98% -5.78 MIRM /fcf-yield <GO>
Operating Margin -21.50% -4.20% -17.30 MIRM /operating-margins <GO>
Net Profit Margin -21.20% -4.50% -16.70 MIRM /net-margins <GO>
Revenue Growth (YoY) 22.00% 54.70% -32.70 MIRM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.84 6.29 +4.55 COGT /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 MIRM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.2 48.4 -1.20 MIRM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 0.99 +0.06 COGT /macro-sensitivity <GO>
Forward P/E Multiple 22.0x 32.0x -10.00 COGT /forward-pe <GO>
Enterprise Scale & Market Cap $5.38B $5.52B -$136.5M MIRM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COGT REV MIRM REV COGT GROSS % MIRM GROSS % COGT FCF MIRM FCF
FY 2025 $933.4M $521.3M — — -$266.0M $54.9M
FY 2024 $772.6M $336.9M — — -$208.4M $9.3M
FY 2023 $582.8M $186.4M — — -$153.6M -$79.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
MIRM // BETA 0.99